Oxford Nanopore Technologies (ONT) Piper Sandler 36th Annual Healthcare Conference summary

Technology overview and differentiation

• Nanopore technology enables sequencing of previously unmapped DNA regions, providing valuable insights for diseases like cancer and Alzheimer's.

• The platform reads both DNA and RNA, with future plans to sequence proteins and other molecules, offering scalability from handheld to large instruments.

• Electronic sequencing allows for flexible device sizes and multi-omics capabilities.

Recent innovation and product development

• Achieved over 99% accuracy in nanopore sequencing, integrating real-time workflows and informatics.

• Scaled to process over 100,000 genomes, including large-scale programs like the Emirati Genome Program.

• Launched P2 instruments for decentralized human genetics labs at $10,000, with over 1,350 units worldwide.

• Developed Q-Line for locked-down, end-to-end workflows targeting clinical and applied markets.

• Focus on expanding into multi-omics and increasing information richness.

Competitive landscape and market positioning

• Industry trends validate the focus on information richness, affordability, and multi-omics.

• Nanopore leads in epigenomics accuracy and offers $500 30x human genomes, matching competitors on cost.

• Released NOMIS protocol for microbial sequencing, achieving high accuracy in pathogen detection.